Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Lexeo Therapeutics

Clinical trials sponsored by Lexeo Therapeutics, explained in plain language.

Lexeo Therapeutics LXEO NASDAQ

Develops gene therapies for cardiovascular and CNS diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Not yet finished but already full! 3 Completed 1

Gene therapy targets Alzheimer's in High-Risk group

Disease control Completed

This early-stage trial tested a gene therapy called LX1001 in 15 people with Alzheimer's who have two copies of the APOE4 gene, a high-risk form. The therapy delivers a healthy APOE2 gene to try to change the course of the disease. The main goal was to check safety and side effec…

Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 07:55 UTC